Thank you for logging into today’s event. Please note we are in standby mode. All Microphones will be muted until the event starts. We will be back with speaker instructions @ 11:55 am. Any Questions? Please email: info@theknowledgegroup.org

**Group Registration Policy**

Please note ALL participants must be registered or they will not be able to access the event.

If you have more than one person from your company attending, you must fill out the group registration form.

We reserve the right to disconnect any unauthorized users from this event and to deny violators admission to future events.

To obtain a group registration please send a note to info@theknowledgegroup.org or call 646.202.9344.
Attendee’s your lines are on listen only, please note that the event is being recorded for playback purposes.

On the right-hand side of your screen you will see the chat window, in this window you will see answers to some of our most frequently asked questions as well as the contact details of our speakers at today’s event.

You can submit a question to our speakers at any time using this chat window, although your question won’t appear in the window it will be collected for the question and answer section towards the end of today’s event.

The “Settings” button in the bar at the top of the screen will bring up additional information about today’s event and some troubleshooting tips.

In the event of any technical problems, we request you refresh the event page, if these issues persist please give us a call on 646-844-0200 and we’ll be able to help you.
If anyone was unable to log in to the online Webcast and needs to download a copy of the PowerPoint presentation for today’s event, please send an email to: info@theknowledgegroup.org. If you’re already logged in to the online Webcast, we will post a link to download the files shortly and you can see that in the chat window.

During the webcast, you’ll be sent a survey via email asking you for your feedback regarding your experience with this event today. If you are applying for continuing education credit, completions of the surveys are mandatory as per your state boards and bars. Three secret words will be given throughout the presentation. We will ask you to fill these words into the survey as proof of your attendance. Please stay tuned for the secret word. If you miss a secret word, please refer to the information in the chat window.

Follow us on Twitter, that’s @Know_Group to receive updates for this event as well as other news and pertinent info.

Speakers, I will be giving out the secret words at randomly selected times. I may have to break into your presentation briefly to read the secret word. Pardon the interruption.
We need your insights -- We are conducting some special research to improve The Knowledge Group for you.

Give us ten minutes on the phone and we will give you three months of FREE CE webcasts.

Please click the link found in the upper right “Chat Box” to sign up and participate. We look forward to hearing from you.
Buchanan Ingersoll & Rooney PC brings true partnership to our clients. With close to 500 attorneys and government relations professionals in 17 offices in the United States, we have formalized a model for consistently delivering the service attributes our clients most value. A nationally recognized firm, we provide a wide range of services in the areas of intellectual property, health care, financial services and banking, litigation, labor and employment, real estate, corporate and business law, tax, energy, and government relations.

Consistently ranked among the top intellectual property firms in the nation and worldwide, Knobbe Martens has over 275 lawyers and scientists nationwide and dedicates its practice to all aspects of intellectual property and technology law, including litigation. Knobbe Martens serves a diverse group of clients from multinational corporations to emerging businesses of all stages. The firm is headquartered in Orange County, California, with offices in Los Angeles, New York, San Diego, San Francisco, Seattle, Silicon Valley and Washington, D.C., and enjoys an international reputation for excellence. More information about the firm can be found at www.knobbe.com.
Erin M. Dunston is the Biotechnology practice group leader of Buchan Ingersoll & Rooney’s Intellectual Property section and a member of the firm’s Associates Committee. She focuses on disputes before the Patent Trial and Appeal Board, district court litigation, opinions, and prosecution — primarily in the fields of biotechnology, pharmaceuticals, and medical devices. Her district court litigation practice includes classic infringement and declaratory judgment cases, as well as Paragraph IV cases.

Kerry S. Taylor, Ph.D. is a Partner in the Knobbe Martens San Diego office, practicing intellectual property law since 1998 in areas including Inter Partes Reviews, patent litigation, patent prosecution, strategic planning and counseling relating to infringement and licensing issues, and IP due diligence studies. Kerry is very active in the firm’s post-grant practice and serves as the chief editor of the firm’s PTAB blog (https://www.knobbe.com/blog/ptab). He received his doctorate degree in biochemistry and molecular biology from the University of Chicago and was awarded the Lucille P. Markey award for his work in the field of structural biology, using primarily x-ray crystallographic techniques to study protein engineering and design. After receiving his doctorate degree, Kerry received his J.D. degree from the University of California – Berkeley School of Law.
Post-Grant Review: Challenging the Validity of Patents

For the past years, several provisions from the United States Patent and Trademark Office (USPTO) were made to review the validity of granted patents. Due to the changing U.S. patent system, the American Invents Act (AIA) established post-grant reviews to validate patents in a much wider range of invalidity grounds and applications.

However, with the growing number of significant changes brought by the AIA to the U.S. patent system, more issues qualify for PGR and preemptive challenges arise that generally affect the patent landscape. While the validity of patents is still in question, some claims were found out to be invalid and many of these petitions are still pending, raising a heightened concern among the patent owners and companies. With only few among PGR petitions granted, PGR primarily aims to challenge unpatentable claims, review the patentability of such claims on trial proceedings and produce more grounds to challenging the validity of patents.

In this LIVE Webcast, a panel of distinguished professionals and thought leaders brought together by The Knowledge Group will help the audience understand the fundamental aspects of Post-Grant Reviews. They will also provide an in-depth discussion of the challenges in verifying the validity of patents and the best strategies to avoid potential legal risks and threats.

Key topics include:

- An Overview of Post-Grant Review
- PGR Proceedings: Key Issues and Considerations
- Timing and Procedural Considerations for Petitioners and Patent owners in view of SC's upcoming decision in Oil States
- Statutory Grounds Against Patents Claims
- Sovereign Immunity moot all AIA Trials
- Aqua Products and Motions to Amend
- Patent's Validity: Challenging Grounds and Range of Validities
- Patent Eligibility Claims and Judicial Exceptions
- Practice Tips on PGR Petitions
- Trends, Developments and What Lies Ahead
For more information about the speakers, you can visit: https://theknowledgegroup.org/event-homepage/?event_id=2614
Numbers, Trends, Outcomes

Petitions by Trial Type
(All Time: 9/16/12 to 9/30/17)

- IPR: 6,955 (92%)
- CBM: 524 (7%)
- PGR: 78 (1%)

Total: 7,557
Numbers, Trends, Outcomes

- As of October 31, 2017, 82 PGR Petitions have been filed

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Number of Petitions Filed</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>2</td>
</tr>
<tr>
<td>2015</td>
<td>11</td>
</tr>
<tr>
<td>2016</td>
<td>24</td>
</tr>
<tr>
<td>2017</td>
<td>41</td>
</tr>
<tr>
<td>2018</td>
<td>4</td>
</tr>
</tbody>
</table>
### Post-Grant Review: Challenging the Validity of Patents

#### Numbers, Trends, Outcomes

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Petitions Filed</th>
<th>Instituted (%)</th>
<th>Settlements/Terminations</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>2</td>
<td>0 (0%) (Both Terminated Prior to Institution)</td>
<td>2</td>
</tr>
<tr>
<td>2015</td>
<td>11</td>
<td>10 (91%) (Only 2015-00023 not)</td>
<td>0</td>
</tr>
<tr>
<td>2016</td>
<td>24</td>
<td>9 (41%)</td>
<td>2</td>
</tr>
<tr>
<td>2017</td>
<td>41 (16 Eligible)</td>
<td>8 (50%)</td>
<td>2</td>
</tr>
<tr>
<td>2018</td>
<td>4</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### Post-Grant Review: Challenging the Validity of Patents

**Numbers, Trends, Outcomes**

In The Petitions

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>101</th>
<th>102</th>
<th>103</th>
<th>112 W</th>
<th>112 E</th>
<th>112 I</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>2015</td>
<td>6</td>
<td>7</td>
<td>10</td>
<td>1</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>2016</td>
<td>4</td>
<td>9</td>
<td>21</td>
<td>8</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>2017</td>
<td>1</td>
<td>7</td>
<td>49</td>
<td>8</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>2018</td>
<td>0</td>
<td>4</td>
<td>20</td>
<td>2</td>
<td>3</td>
<td>6</td>
</tr>
</tbody>
</table>
# Most Successful Bases

**In The Petitions/Institution Decision**

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>101</th>
<th>102</th>
<th>103</th>
<th>112 W</th>
<th>112 E</th>
<th>112 I</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>0/0</td>
<td>1/0</td>
<td>1/0</td>
<td>2/0</td>
<td>2/0</td>
<td>2/0</td>
</tr>
<tr>
<td>2015</td>
<td>6/3</td>
<td>7/2</td>
<td>10/9</td>
<td>1/0</td>
<td>3/0</td>
<td>3/1</td>
</tr>
<tr>
<td>2016</td>
<td>4/0</td>
<td>9/2</td>
<td>21/6</td>
<td>8/2</td>
<td>7/2</td>
<td>6/3</td>
</tr>
<tr>
<td>2017</td>
<td>1/0</td>
<td>7/0</td>
<td>49/10</td>
<td>8/3</td>
<td>9/2</td>
<td>8/3</td>
</tr>
<tr>
<td>2018</td>
<td>0</td>
<td>4</td>
<td>20</td>
<td>2</td>
<td>3</td>
<td>6</td>
</tr>
</tbody>
</table>
Joinder, Disclaimer, Settlement

- Joinder is a rare event (requested once, and denied)
- Disclaimer occurs (all claims in 3 cases, select claims in others); Board generally denies institution if disclaimed early enough
- Settlements – generally via Joint Motion to Terminate and generally granted
Common Threads

- More prose-based arguments rather than claim charts
- Liberal use of annotations in graphics
- Highly-sophisticated citation to prior Board decisions
- Most patent owners file Preliminary Responses and most are supported with expert testimony
- Claim construction/eligibility a greater focus
Aqua Products and Motions to Amend
Motion to Amend Statistics

<table>
<thead>
<tr>
<th>Reasons Provided for Denying Entry of Substitute Claims*</th>
<th># of Cases</th>
<th>Pct</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reasons Based in Whole or Part on 35 U.S.C.:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>101 Non-Statutory Subject Matter</td>
<td>7</td>
<td>6%</td>
</tr>
<tr>
<td>112(a) Written Description</td>
<td>9</td>
<td>8%</td>
</tr>
<tr>
<td>112(b) Definiteness</td>
<td>1</td>
<td>1%</td>
</tr>
<tr>
<td>102/103 Anticipated/Obvious Over Art of Record</td>
<td>41</td>
<td>35%</td>
</tr>
<tr>
<td>316(d)(3) Claims Enlarge Scope of Patent</td>
<td>6</td>
<td>5%</td>
</tr>
<tr>
<td>316(d)(1)(B) Unreasonable # Substitute Claims</td>
<td>3</td>
<td>3%</td>
</tr>
<tr>
<td>Multiple Statutory Reasons Given**</td>
<td>27</td>
<td>23%</td>
</tr>
<tr>
<td>Reasons Based Solely on Procedure:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cases Where Only Procedural Reasons Given</td>
<td>22</td>
<td>19%</td>
</tr>
<tr>
<td>Totals:</td>
<td>116</td>
<td>100%</td>
</tr>
</tbody>
</table>

* 116 MTAs requesting entry of substitute claims have been denied in whole or in part.
** Of the "Multiple Statutory Reasons Given" trials, 24 of the 27 trials included "Anticipated/Obvious" as a reason.

How Many Motions to Amend Substituting Claims Are Granted?

- 2, 2% Granted
- 4, 3% Granted in Part
- 112, 95% Denied

Data current as of: 4/30/2016

USPTO MTA Study at 4.
Aqua Products – factual background

- Patent Owner Aqua Products filed a motion to amend in IPR
  - Board determined that Aqua Products did not demonstrate patentability of the amended claims
    - Board issued Final Written Decision (FWD) denying motion to amend
- Aqua Products appealed FWD to the Federal Circuit
  - Federal Circuit panel unanimously affirmed FWD
    - Panel: Reyna, Prost, Stark (by designation)
- Aqua Products sought rehearing en banc
Aqua Products - result

The only legal conclusions that support and define the judgment of the court are: (1) the PTO has not adopted a rule placing the burden of persuasion with respect to the patentability of amended claims on the patent owner that is entitled to deference; and (2) in the absence of anything that might be entitled deference, the PTO may not place that burden on the patentee. All the rest of our cogitations, whatever label we have placed on them, are just that—cogitations. Even our discussions on whether the statute is ambiguous are mere academic exercises.

The final written decision of the Board in this case is vacated insofar as it denied the patent owner’s motion to amend. The matter is remanded for the Board to issue a final decision under § 318(a) assessing the patentability of the proposed substitute claims without placing the burden of persuasion on the patent owner. The Board must follow this same practice in all pending IPRs unless and until the Director engages in notice and comment rule-making. At that point, the court will be tasked with determining whether any practice so adopted is valid.

VACATED AND REMANDED


O’Malley opinion at 66.
**Aqua Products – Next Steps**

PTAB has been issuing orders where the petitioners are now permitted a sur-reply as the final brief filed for proceedings with a motion to amend.

**Petitioner – Practice Tips**
- Ask for a Sur-Reply if patent owner filed a motion to amend
- Likely to see more motions to amend (so plan ahead when preparing petition challenging patent)

**Patent Owner – Practice Tips**
- Consider motion to amend
- Keep in mind that percentage of granted motions to amend may not change significantly
Sovereign Immunity as Inter Partes Defense
Sovereign Immunity -- 11th amendment

- States are sovereign under the 11th amendment, and therefore immune from lawsuits unless the state waives or Congress abrogates
- Has been extended to state universities and state university research foundations
- The USPTO found that Sovereign Immunity applies to IPR proceedings
The Case That Started it All

- **Covidien LP v. Univ. of Florida Research Found., Inc. (IPR2016-01274, IPR2016-01275, IPR2016-01276)**
  - Covidien filed IPR petitions against patents owned by UFRF
  - PTAB found:
    - Sovereign Immunity is available as a defense in IPR
    - UFRF is an “arm of the state” and therefore a sovereign
    - PTAB dismissed IPRs based on UFRF’s sovereign immunity
Sovereign Immunity at the PTAB

- Three PTAB panels have found that sovereign immunity applies in IPR
  - In one case, the IPR proceeded without the sovereign present against a non-sovereign co-owner
- PTAB has not yet ruled on whether asserting the patent in district court waives sovereign immunity at the PTAB
  - Several pending cases involve this issue
- It is not clear whether a sovereign immunity decision is reviewable on appeal to the Federal Circuit
**Allergan and Restasis®**

- Allergan has 6 orange book listed patents for Restasis®, and asserted them against several generic pharmaceutical companies.
- The generics filed IPRs against the 6 patents.
- To avoid IPR, Allergan transferred ownership of all 6 patents to the Saint Regis Mohawk Tribe.
- Allergan paid the Tribe $13.75M, with additional royalties of up to $15M/year possible.
- Allergan’s press release stated that the transfer was an attempt to avoid IPR by invoking the Tribe’s sovereign immunity.
Allergan Open Questions

• Briefing is complete on the Tribe’s motion to dismiss the pending IPRs based on sovereign immunity, awaiting the Board’s decision
• The Board has not considered Tribal sovereign immunity before
• Senator McCaskill introduced bill to abrogate Tribal sovereign immunity at PTAB
Constitutionality of PTAB Trials: *Oil States*
Oil States - History

- Patent Owner Oil States lost at PTAB level in IPR
- Oil States appealed to Federal Circuit, arguing that IPRs are unconstitutional
- Federal Circuit affirmed the PTAB holding without issuing a decision (Rule 36 affirmance)
- Oil States appealed to the Supreme Court
- Supreme Court agreed to hear the case
Oil States at the Supreme Court

• **Issue:** Whether *inter partes* review, an adversarial process used by the Patent and Trademark Office (PTO) to analyze the validity of existing patents, violates the Constitution by extinguishing private property rights through a non-Article III forum without a jury.

• What’s at stake: the future of all IPRs/PGRs/CBMs

• Over 40 Amicus Briefs filed

• Parties’ briefing is complete

• Oral Argument scheduled for November 27, 2017
**Oil States – Are Patents Public or Private Rights?**

- **Article III** – Only an Article III Court can decide a suit at common law or in equity. *Stern*, 564 U.S. 462, 484 (2011).
  - Suits deciding **public rights** are an exception. *Id.* at 485.

- **Are patents private rights?**

- **Are patents public rights?**
  - *Gayler*, 51 U.S. (10 How.) 477, 494 (1851) – “The [patent] monopoly did not exist at common law, and the rights, therefore, which may be exercised under it cannot be regulated by the rules of the common law.” See also, *Murray’s Lessee*, 59 U.S. (18 How.) 272, 284 (1856); *MCM Portfolio*, 812 F.3d 1284, 1293 (Fed. Cir. 2015).
Oil States – Going Forward

- Decision expected in first half of 2018
- Petitioner - Practice Tips
  - Weigh waiting to file petition vs. delay
    - 1-year statutory bar
    - Stay of litigation
    - Clearance on product development
- Patent Owner – Practice Tips
  - Maintain pendency of case
    - Request rehearing
    - Appeal to Federal Circuit
Q&A:

► You may ask a question at anytime throughout the presentation today. Simply click on the question mark icon located on the floating tool bar on the bottom right side of your screen. Type your question in the box that appears and click send.

► Questions will be answered in the order they are received.
Post-Grant Review: Challenging the Validity of Patents

Key Discussion Points:

The speakers will summarize the key takeaways of their presentations.

Erin M. Dunston
Shareholder
BUCHANAN INGERSOLL & ROONEY PC
erin.dunston@bipc.com
703 838 6645

Kerry S. Taylor, Ph.D.
Partner
Knobbe Martens
Kerry.Taylor@knobbe.com
858-707-4000

Kerry S. Taylor, Ph.D.
Partner
Knobbe Martens
Kerry.Taylor@knobbe.com
858-707-4000
ABOUT THE KNOWLEDGE GROUP

The Knowledge Group is an organization that produces live webcasts which examine regulatory changes and their impacts across a variety of industries. “We bring together the world’s leading authorities and industry participants through informative webcasts to study the impact of changing regulations.”

If you would like to be informed of other upcoming events, please click here.

DISCLAIMER:

The Knowledge Group is producing this event for information purposes only. We do not intend to provide or offer business advice.

The contents of this event are based upon the opinions of our speakers. The Knowledge Group does not warrant their accuracy and completeness. The statements made by them are based on their independent opinions and does not necessarily reflect that of The Knowledge Group’s views.

In no event shall The Knowledge Group be liable to any person or business entity for any special, direct, indirect, punitive, incidental or consequential damages as a result of any information gathered from this webcast.

Certain images and/or photos on this page are the copyrighted property of 123RF Limited, their Contributors or Licensed Partners and are being used with permission under license. These images and/or photos may not be copied or downloaded without permission from 123RF Limited.